The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance.
J. Fok
No relevant relationships to disclose
R. Kurzrock
Honoraria - Genentech; Merck
Research Funding - Merck; Roche
Other Remuneration - Merck
A. M. Tsimberidou
No relevant relationships to disclose
S. Wen
No relevant relationships to disclose
A. Naing
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
F. Janku
No relevant relationships to disclose
G. S. Falchook
No relevant relationships to disclose
S. A. Piha-Paul
No relevant relationships to disclose
R. Katz
No relevant relationships to disclose
S. Fu
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. J. Wheler
No relevant relationships to disclose